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Two thirds of all breast cancers are characterized by the expression of estrogen 
receptor (ER) α, encoded by the gene ESR1. Mutations in the ligand binding domain 
(LBD) of ESR1 have been identified as a resistance mechanism in patients who have 
progressed on endocrine therapies. In order to better understand the clinical 
significance of these mutations, two novel approaches for studying ESR1 activating 
mutations were developed. First, we characterize the two most prevalent ESR1 
mutations, Y537S and D538G, through gene editing of the endogenous loci in ER-
expressing human breast epithelial cells. In in vitro and in vivo assays, both ESR1 
Y537S and D538G knockins demonstrate estrogen independent proliferation and tumor 
xenograft formation. Additionally, ESR1 mutations confer resistance to tamoxifen, 
fulvestrant and palbociclib but not some combination therapies. Both ESR1 Y537S and 
D538G knockins are selected for under endocrine treatment when cultured with MCF7 
parentals cells in vitro, with the ESR1 Y537S knockin showing increased resistance 
compared to the ESR1 D583G knockin. Moreover, when co-cultured together under 
estrogen deprived conditions, the ESR1 Y537S knockin cells outcompete the ESR1 
D538G knockin cells, in vitro and in vivo. Taken together, these results suggest that 
functional modeling of ESR1 mutations can provide insight on mechanisms for 
resistance, how these resistance mutations can be selected and effective drug 
combinations for the treatment of endocrine resistance breast cancers. Second, given 
the problem of tumor heterogeneity in breast cancer, the true frequency of ESR1 
mutations may be underestimated since mutational profiles can vary between different 
sites of metastatic disease.  Here, we detect a higher frequency of ESR1 mutations in 
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circulating plasma tumor DNA (ptDNA) using droplet digital PCR (ddPCR). We obtained 
blood from eleven patients with known ESR1 mutational status identified by next 
generation sequencing of biopsied metastatic tissues.  All corresponding ESR1 
mutations were detected in ptDNA, with two patients harboring additional ESR1 
mutations not present in metastatic tissues.  In a prospective cohort, metastatic tissue 
and plasma were collected contemporaneously from eight ER-positive and four ER-
negative patients. Although no ESR1 mutations were identified in tissue biopsies, 
ddPCR detected seven ESR1 mutations in ptDNA from six of the eight ER-positive 
patients (75%).  We show that ESR1 mutations occur at high frequency and that blood 
can be used to identify additional mutations not found by sequencing of a single 
metastatic lesion. 
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Breast cancer and genetics overview 
 Despite cancer associated deaths steadily declining over the last two 
decades, breast cancer remains the most commonly diagnosed cancer in women 
in the United States1. Each year, approximately 1 in 8 women will be diagnosed 
with breast cancer and in 2015, there were approximately 232,000 new cases of 
breast cancer and 40,000 deaths. In the United States, breast cancer remains 
the second leading cause of death in women2. It is now widely accepted that 
breast cancer is primarily a genetic disease, influenced by both the presence of 
susceptibility factors and the accumulation of oncogenic changes and alterations 
in tumor suppressor genes3. Under the right conditions, these genetic alterations, 






enhance the fitness of a normal cell, leading to the development and growth of a 
tumor.  
Although breast cancer is commonly summarized as a singular disease, it 
can be further stratified into 21 different histological subtypes depending the 
genes that are expressed4. While these classifications can provide prognostic 
value and who is likely to benefit from adjuvant endocrine or chemotherapy, 
breast cancer is commonly classified into molecular subtypes based on the 
presence or absence of several receptors. These receptors include estrogen 
receptor (ER), progesterone receptor (PR) and amplification of human epithelial 
growth factor receptor 2 (HER2), making up the four different subtypes: luminal 
A, luminal B, HER2+ and triple negative5. Classification of breast cancer into 
these subtypes has led to the understanding of how these receptors drive and 
promote the survival of cancer cells. More importantly, knowledge of these 
pathways has led to the development of specific inhibitors that can repress 
cancer growth.  
 Estrogen receptor positive breast cancer accounts for approximately 70% 
of all breast cancer cases. By definition, this cancer subtype is primarily driven by 
the hormone estrogen. Since the identification of ER in the late 1950s, endocrine 
therapies have been developed that modulate ER signaling through repression of 
downstream effectors or inhibiting the synthesis of endogenous estrogen. While 
these therapies have been effectively in treating women with ER-positive breast 
cancer, prolonged exposure to these drugs invariably leads to resistance. Recent 
genome sequencing studies have revealed that activating mutations in the gene 
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that codes for ER, ESR1, is responsible for acquired resistance to endocrine 
therapies6-10. ESR1 mutations cluster in the ligand binding domain of ER and 
understanding how they confer drug resistance can elucidate pathways and 
targets that can resensitize these cells to endocrine therapies. 
 
ESR1 background and function 
Discovery of ESR1 
While the nuclear hormone receptor ERɑ protein was not purified and 
isolated until the late 1970s, the role of estrogen and its receptor in breast cancer 
progression was well cited before its discovery. In 1896, George Beatson 
reported that removal of the ovaries in premenopausal women with advanced 
breast cancer reduced the size of tumors and improved patient’s prognosis11. 
This was based on the observation that the size of a breast tumor increased and 
decreased during a woman's menstrual cycle, suggesting that a key regulator 
was derived from the ovaries. This practice would be furthered by Stanley Boyd 
in 1900, citing that a third of his patients with breast cancer benefited from 
ovarian ablation12. Allen and Doisy, in 1923, noticed that mice that undergone a 
double ovariectomy failed to exhibit periodic growth in the epithelium lining their 
genital tract. However, injection of ovarian extracts into mice restored growth in 
the genital tract, demonstrating that the steroid hormone estrogen was produced 
in the ovaries13. Estrogen receptor was first described by Elwood Jensen in 1958. 
Jensen utilized tritiated estradiol and found the highest amounts localized to the 
uterus, vagina and ovaries when injected into female mice14. Subsequently, in 
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1980, Geoffrey Greene along with Jensen, purified ER protein from human 
breast epithelial MCF7 cells by passing cytosolic extract through an estrogen 
affinity column and subsequently developed a monoclonal antibody to ER15. This 
seminal study provided the groundwork for the eventual cloning of the estrogen 
receptor in the mid 1980s16-17.  
 
ESR1 gene and protein structure  
The ESR1 gene is located on chromosome 6q25.1 and contains 10 coding 
exons. The ESR1 gene has 13 different splicing variants with the dominant ESR1 
mRNA transcript variant encoding a 67 kDa nuclear receptor protein and is 
comprised of 595 amino acids. ERɑ (also known as NR3A1) belongs to a family 
of nuclear receptor family of transcription factors that also includes ERβ (also 
known as NR3A2), encoded by ESR2. The ESR2 gene is located on 
chromosome 14q23.2 and contains 14 coding exons. ESR2 has 13 different 
splicing variants but unlike ESR1, several splice variants are expressed in 
tissues. However, what is currently regarded as the wild type ERβ is 63kDa and 
comprised of 530 amino acids. It is important to note that although the action of 
estrogen is now known to be mediated through the interactions of both of these 
estrogen receptors, ERβ was not cloned until the mid 1990s18. The interaction 
between these two receptors and their contribution to estrogen mediated 
signaling is still being unraveled. Therefore, any subsequent mention of the 
estrogen receptor refers to ERɑ, unless otherwise stated. 
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In order to determine the different functional domains of the estrogen 
receptor, initial molecular cloning experiments focused on confirming the 
sequence of human ER cDNA and comparing it to other steroid hormone 
receptors for homology16-17, 19. These comparison studies revealed six regions of 
variable conservation, namely regions A to F, that helped elucidate their function. 
Regions A, C and E were found to be highly conserved and separated by regions 
of lower homology, B, D and F20. Region A/B and E make up the activation 
domains AF-1 and AF-2 domains respectively21. AF-2 is also known as the ligand 
binding domain (LBD). Upon ligand binding, ER undergoes a conformational 
change that facilitates that recruit a range of coregulatory proteins. Interestingly, 
although transcriptional activation involves the synergy between the two AF 
domains, only AF-2 is entirely dependent on ligand binding activity22. Region C is 
highly hydrophilic, consisting of basic amino acids and cysteines, and forms the 
DNA-binding domain (DBD), responsible for recognition of estrogen response 
elements (ERE) and DNA binding. Region D is the hinge region, linking the DBD 
and LBD together. Lastly, region F is important for modulating gene transcription 
and regulating receptor dimerization23-24. 
 
Estrogen signaling 
Estrogen receptors are primarily activated by its cognate hormone 
estrogen. The most potent estrogen produced in the body is 17β-estradiol (E2). 
Two other metabolites of estrogen, estrone and estriol, also exist but are weaker 
agonists of ER. Interestingly, the binding pocket in the ligand binding domain of 
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ER also permits the binding of other estrogen mimetics such as phenol red as 
well as other environmental contaminants, allowing for downstream signaling in 
the absence of E225.  
Estrogens and estrogen receptors stimulate target gene expression 
through two primary mechanisms: “classical” and “non-classical” signaling. 
During “classical” signaling, ligand binding induces receptor dimerization and 
transcriptional activation. Activated ER complexes are able to recognize 
palindromic sequences known as estrogen response elements located in the 
promoters of target genes. Additionally, ligand binding induces a conformational 
change that permits the recruitment and binding of a variety of coregulators, such 
as SRC1, AIB1, BCAS3 and PELP-1 that alter chromatin structure and facilitate 
the recruitment of RNA polymerase II for transcription initiation. Notably, the 
collection of co-activators and co-repressors that modulate ER signaling differ 
depending on the tissue type, a balance that is especially important in anti-
estrogen therapy. 
About a third of the genes in humans that are regulated by ER do not 
contain or only contain half of the ERE sequence and thus, are regulated in a 
“non-classical” manner26. During “non-classical” signaling, ER can regulate target 
gene expression without directly binding to DNA by tethering to other 
transcription factors in the nucleus. Transcription factors such as AP-1, SP-1, SF-
1 and NF-κB can interact with ER, enhancing the recognition and initiation of 
transcription at alternative response elements27. This mechanism is common 
among other nuclear hormone receptors and is referred to as transcriptional 
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cross-talk28. Additionally, studies are increasingly demonstrating that the 
estrogen receptor can undergo a number of posttranslational modifications that 
include phosphorylation, methylation, acetylation, sumoylation and ubiquitination 
with the most documented being phosphorylation. Serines and tyrosines along 
the AF-1 and hinge domain of ERɑ can be activated by MAP kinase, AKT, 
protein kinase A, and HER2, leading to downstream signaling in the absence of 
ligand29-30. 
Lastly, while estrogens predominantly exert their effects through the two 
canonical pathways listed above, some effects of estrogen are so instantaneous 
that they could not be dependent on RNA activation and protein synthesis. This 
last category is known as non-genomic signaling and is thought to be mediated 
by membrane associated ER and the activation of various protein-kinase 
cascades31. The most well-studied of these non-genomic actions is through 
activation of the MAP kinase and phosphoinositol (PI) 3-kinase signaling cascade 
32-33. Collectively, the interactions of all of these intersecting pathways highlight 
the profound effects of estrogen on growth and differentiation on the different 
target tissues in the body. 
 
1c. Clinical Importance of ER in breast cancer 
In addition to its role in development and morphogenesis, ER has been 
long acknowledged as a major driver in breast cancer. Approximately 70% of all 
breast cancers express estrogen receptor. Studies have shown that luminal 
breast epithelial cells are characterized by high expression of ESR1 whereas 
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other tumor types show little to no expression of this gene34. Thus, ER-
expressing breast cancers are normally classified under the luminal subtype. 
Luminal breast cancers are further divided into luminal A and B, with luminal B 
characterized by high levels of HER2 or Ki67 cells35. Luminal A breast cancers 
have been shown to be associated with better clinical outcomes when compared 
to other subtypes. This is largely due to ER expression correlating with lower 
tumor grade, lower tumor proliferation, less amplification of HER2 oncogene, 
retention of the p53 tumor suppressor gene and slower rates of disease 
recurrence. Additionally, compared to the triple negative subtype, there are a 
growing number of therapies that inhibit ER and ER signaling. 
Since the identification of ER in the late 1950s, it has been a subject of 
immense research and a target for the development of cancer therapies. 
Endocrine therapies for the treatment of ER-positive breast cancer work by a 
number of mechanisms but all aim to antagonize estrogen mediated signaling. 
Three types of endocrine therapies exist for the treatment of ER-positive breast 
cancers: selective estrogen receptor modulators (SERMs), selective estrogen 
receptor degraders (SERDs) and aromatase inhibitors (AI). SERMs, such as 
tamoxifen, bind to ER and recruit co-repressors which prevent transcriptional 
activation and the production of downstream effectors36-37. SERDs, like 
fulvestrant, modulates ER signaling by promoting the proteasomal degradation of 
ER38. Lastly, aromatase inhibitors regulate the amount of estrogen present by 
blocking the conversion of androgens to estrogens and in postmenopausal 
women, can result in a 98% decrease in circulating levels of estrogen39. In 
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premenopausal women, tamoxifen or ovarian suppression, either by 
pharmacological inhibition or surgical removal, is standard of treatment. 
 
Identification of ESR1 activating mutations in hormone-resistant metastatic 
breast cancer 
While endocrine therapies remain the mainstay for the treatment of ER-
positive breast cancers, approximately 30% of ER-positive breast cancers exhibit 
de novo resistance and another 40% acquire resistance to these therapies after 
prolonged exposure. Several clinical observations revealed that in approximately 
20% of patients treated with endocrine therapies, reduced expression of ER was 
observed40-41. These findings suggest that these tumors are no longer driven by 
estrogen and likely that alternative pathways have been activated. Secondly, 
upregulation of HER2 has been shown to be associated with insensitivity to 
estrogen therapies42-43. This is possible since data suggest that HER2 may 
reduce levels of ER, thus rendering a tumor less responsive to estrogen44. 
Additionally, PR is commonly loss in ER-positive breast cancer patients who are 
treated with endocrine therapies and PR loss has been shown to be associated 
with increased growth factor signaling which can subsequently downregulate 
ER44-45. 
Large scale sequencing projects have profoundly transformed our ability 
to understand cancer biology on the genetic level. In the seminal study, Wood et 
al. utilized Sanger sequencing to unravel the range and frequency of genetic 
alterations that make up breast and colorectal tumors, now known as the “cancer 
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genome landscape” 46. Rather than stochastically distributed, the genes that are 
commonly mutated can be divided into two groups based on the frequency found 
across tumors: “mountains” which are frequently mutated and likely to drive 
cancer initiation and progression and “hills” which are less frequently mutated 
and likely harmless. These “mountains” include TP53, PIK3CA, APC, KRAS 
among many others46-47. It comes as a surprise that despite estrogen signaling 
being a key driver of ER-positive breast cancers, mutations have been largely 
absent in the estrogen receptor48. Recently, several groups shed light on a 
decade old conundrum in breast cancer genetics. These studies collectively 
highlighted that estrogen receptor did, in fact, exhibit hotspot mutations but only 
in patients who had metastatic ER-positive breast cancer and had progressed on 
endocrine therapy6-10. Patients who were ER-negative, were not treated with any 
endocrine therapies or were presented with primary disease did not exhibit these 
activating mutations9. Thus, ESR1 mutations do not drive ER-positive breast 
cancer but mediate endocrine resistance. Interestingly, the idea of an ESR1 
activating mutation conferring estrogen independent transactivation was first 
proposed in 1997 by Suzanna Fuqua49. However, the small sample size of the 
study (n=1) and the failure of subsequent genome wide sequencing studies to 
identify similar lesions could possibly explain why these activating mutations 
have eluded discovery for such a long time48. 
Collectively, previous studies investigating the functional consequence of 
mutations in the ligand binding domain of ESR1 have strongly suggested that the 
overexpression of these mutations induce estrogen independence and confer 
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resistance to endocrine therapies. Indeed, the first clue originates from a study 
by Li et al. utilizing patient derived xenograft (PDX) mouse models with tumor 
cells derived from primary and advance breast cancers that were resistant to 
endocrine therapies6. RNA-sequencing data from two of the PDX mice revealed 
the ESR1 Y537S and E380Q mutations were present in the majority of reads. 
When MCF7 and T47D cells were stably transduced with lentiviral vectors to 
overexpress the ESR1 Y537S mutation, both cell lines exhibited estradiol 
independent proliferation, although MCF7 cells retain some estradiol 
responsiveness. Moreover, the addition of fulvestrant only partly inhibited the 
proliferation of the ESR1 Y537S mutant compared to significant inhibition in the 
parental cell lines. 
Shortly after the study by Li et al., two concurrent genome wide 
sequencing studies characterizing tumors from patients with advance ER-positive 
breast cancer treated with anti-estrogen therapies and aromatase Inhibitors 
revealed additional ESR1 mutations that cluster in the ligand binding domain of 
ER7-8. In addition to the aforementioned ESR1 Y537S mutation, the ESR1 
L536Q/R, Y537N/C, and D538G mutations were reported. Using HEK293T cells 
co-transfected with an ERE-firefly luciferase reporter plasmid and various ESR1 
constructs, Robinson et al. demonstrated strong constitutive transactivation of 
the ERE reporter by the ESR1 mutants in the absence of estrogen. Moreover, it 
was found that although the ESR1 mutants could be inhibited by tamoxifen and 
fulvestrant in a dose-dependent fashion, the IC50 was two to four fold higher for 
the mutants compared to cells expressing wild-type ESR1. Similar results were 
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seen by Toy et al. in MCF7 and SK-BR-3 cells when mutant ESR1 was 
cotransfected with a luciferase report construct8.  When nude mice were injected 
with MCF7 cells contained doxycycline induced vectors with these ESR1 LBD 
mutations, tumors were able to establish and grow in the absence of E2 
supplementation. Molecular modeling studies have demonstrated that the ESR1 
Y537S and D538G mutations induce a confirmation change in ER to favor the 
agonist confirmation in the absence of any ligand, suggesting constitutive 
activation of ER signaling8, 10.  
 
Isogenic modeling of ESR1 activating mutations 
 To date, an emerging body of evidence has addressed the stark difference 
between oncogenic mutations that have been overexpressed, usually by 
transient or stable transfection of cDNA, or knocked in as a single copy in cell 
lines. In a seminal finding, Konishi et al. described the dramatic differences in 
transformation between K-ras G12V knock-in cells and K-ras G12V 
overexpressing cells50. Surprisingly, when mutant K-ras is knocked into MCF10A 
cells, a non-tumorigenic breast epithelial cell line, the phenotype was minimal yet 
when the same mutant K-ras was overexpressed, MCF10A cells were 
dramatically transformed, exhibited growth factor independence and downstream 
MAP kinase signaling. In addition, other studies have highlighted discrepancies 
in drug sensitivities between cell lines overexpressing mutant cDNA and single 
nucleotide knockin of mutant oncogenes. Notably, overexpression of the HER2 
L755S mutation in MCF10A cells conferred resistance to the tyrosine kinase 
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inhibitor lapatinib51. However, when the same HER2 L755S mutation was 
endogenous expressed as a single copy in MCF10A cells, the MCF10A HER2 
L755S cells did not demonstrate any resistance phenotypes compared to 
parental cells52. Additionally, discrepancies between overexpression of mutant 
cDNA and single nucleotide knockin of mutant oncogenes have been seen in 
studies involving EGFR and AKT153-54.  
In light of the caveats mentioned above, we sought to develop an isogenic 
model to study the functional consequence of a single ESR1 activating mutation 
when driven by an endogenous promoter. This is critical since, to date, ESR1 
mutations have not been found to be associated with amplification of the ESR1 
gene and a more clinically relevant model is needed8. Additionally, it has been 
appreciated that oncogenic changes can cooperate and lead to a more 
transformed phenotype55-56. However, how single knockins can interact with each 
other has not been well characterized. Here, we utilize the ER-expressing breast 
epithelial cell line, MCF7, to create single, heterozygous ESR1 mutants. In this 
study, we focus on the two most common ESR1 mutations, ESR1 Y537S and 
D538G, to investigate their effects on proliferation, tumor formation, estrogen 
independence and resistance to endocrine therapies. Additionally, we evaluated 
the sensitive of these knockins to the CDK 4/6 inhibitor, palbociclib, singly and in 
combination with SERDs and SERMs, since palbociclib has recently been shown 
to be preferentially inhibit the proliferation of luminal ER-expressing breast 
cancer cell lines in vitro57. We also model how these mutations can arise under 
estrogen deprivation and drug selection. Lastly, we demonstrate that although 
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mutations are found on adjacent codons in the LBD, their transformative 





































 Estrogen receptor α (ERα) belongs to a nuclear receptor family of 
transcription factors and is expressed in ~70% of all breast cancer cases. 
Classically, activation of ER signaling leads to the transcription of target genes 
that regulate a wide array of cellular functions that include proliferation, 
differentiation, migration and cell survival. Identification of the estrogen receptor 
has led to the development of endocrine therapies, such as tamoxifen and 
fulvestrant, which directly inhibit ER signaling. In addition to anti-estrogen 
therapies, aromatase inhibitors that suppress the production of estrogen, such as 
exemestane and letrozole, are standard of care in post-menopausal women. 




Despite many ER-positive breast cancer patients responding to these 
drugs, prolonged exposure invariably lead to resistance. Approximately 30% of 
ER-positive breast cancers exhibit de novo resistance with an additional 40% 
acquiring resistance to these therapies59. Genome wide sequencing studies 
involving metastatic breast cancer patients who have progressed on endocrine 
therapies have revealed activating mutations in the ligand binding domain (LBD) 
of the ESR1 gene6-10. Collectively, these studies demonstrate that 
overexpression of these activating mutations induces estrogen independent 
transcription and partial resistance to tamoxifen and fulvestrant.  
 Past studies have highlighted discordant results between single nucleotide 
knockin of mutant oncogenes and overexpression of mutant cDNA50, 53, 60. 
Notably, the HER2 L755S mutation confers resistance to the tyrosine kinase 
inhibitor lapatinib when overexpressed but not when endogenously expressed51-
52. In light of these results, we sought to investigate the effects of the two most 
prevalent ESR1 activating mutations, Y537S and D538G, on transformation 
when driven by an endogenous promoter. Here we utilize adeno-associated viral 
mediated gene targeting to knock in these ESR1 mutations into a human ER-
positive breast epithelial cell line to examine the effects on transformation, drug 
resistance, and how these mutants can arise under selective pressures. 
 
Results 
Gene targeting of single copy, heterogeneous ESR1 activating mutations in a 
ER-positive human breast epithelial cell line 
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In order to model the effects of ESR1 mutations found in ER-positive 
breast cancers, gene targeting was performed using recombinant adeno-
associated virus (AAV) in the MCF7 human breast epithelial cell line. MCF7 is a 
cell line that was derived from a metastatic pleural effusion in a patient with ER-
positive breast cancer and does not contain any activating mutations in ESR161. 
One AAV gene-targeting vector was used as a backbone to introduce the two 
most prominent mutations, ESR1 Y537S and D538G, in the ligand binding 
domain of ESR1 (Figure 2.1A and 2.1B). In each gene targeting experiment, two 
independently derived clones were isolated for each ESR1 mutations. 
Additionally, to control for any potential phenotypic differences caused by gene 
targeting, two independently derived targeted wild-type (TWT) clones were 
generated. Sanger sequencing as well as droplet digital PCR was used to verify 
the incorporation of a single copy of each ESR1 mutation, a 50:50 biallelic ratio, 
and cDNA expression (Figure 2.2A and 2.2B). The cell lines generated and used 
in this study can found in Table 2.1. 
 
ESR1 Y537S and D538G mutations confer estrogen independence in vitro and in 
vivo 
Overexpression studies have demonstrated that ESR1 Y537S and D538G 
mutations induce ligand independent transcriptional activation and estradiol 
independent growth6-10. In order to assess whether single copies of ESR1 Y537S 
and D538G can induce estradiol independent proliferation, we performed growth 
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assays on our MCF7 ESR1 mutants. MCF7 cells require estradiol present in 
media for robust proliferation in culture. 
We found that both MCF7 ESR1 Y537S and D538G cells proliferate in 
serum supplemented media without estradiol compared to MCF7 parental and 
MCF7 TWT cells (Figure 2.3A). In the presence of 1nM β-estradiol (E2), MCF7 
parental cells show proliferation rates similar to MCF7 ESR1 Y537S and D538G 
cells (Figure 2.3B). Interestingly, addition of 1nM estradiol did not increase the 
proliferation of either MCF7 ESR1 mutant cells. Additionally, higher doses of 
estradiol do not stimulate any increased proliferation (data not shown). 
MCF7 cells are able to form tumor xenografts in athymic nude mice in the 
presence of estradiol supplementation. Previously, it has been reported that 
stably transfected MCF7 cells expressing mutant ER were able to induce tumor 
growth after removal of estradiol pellets7. To investigate whether or not single 
copies of ESR1 Y537S or D538G can induce ligand independent tumor 
formation, we injected the MCF7 ESR1 mutant cells into nude mice. We found 
that both MCF7 ESR1 mutant cells, but not MCF7 or MCF7 TWT cells, are able 
to form tumor xenografts in the absence of estradiol supplementation (Figure 
2.4A). However, in the presence of estradiol supplementation, MCF7 wild type 
and MCF7 ESR1 mutant cell lines are able to form dramatically larger xenografts 
when compared to xenografts formed in the absence of estradiol 
supplementation, suggesting that MCF7 wild type and MCF7 ESR1 mutant cells 
are still estrogen responsive in vivo (Figure 2.4B). Taken together, this data 
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suggest that MCF7 ESR1 Y573S and D538G mutations confer estrogen 
independence in ER-positive breast epithelial cells. 
Activating mutations in the ligand binding domain of ESR1 were found in 
metastatic patients who had prolonged exposure to aromatase inhibitors, that is, 
in an estrogen depleted environment. In order to recapitulate how ESR1 mutants 
would be selected under estrogen deprivation, MCF7 cells were cultured together 
in vitro with either MCF7 ESR1 Y537S or MCF7 ESR1 D538G cell lines at a 1:1 
ratio in serum supplemented media with and without estradiol. After 3 weeks, 
both MCF7 ESR1 Y537S and MCF7 ESR1 D538G cell lines were able to 
completely outcompete MCF7 cells when grown in serum supplemented media 
without E2 (Figure 2.5A). When grown in serum supplemented media with 1nM 
E2, MCF7 and both MCF7 ESR1 knock in cells were present in equivalent 
proportions (Figure 2.5B). Moreover, we wanted to see if the ESR1 mutants 
would thrive in an estrogen depleted environment in vivo. When the MCF7 ESR1 
mutant cell lines were co-inoculated in mice with MCF7 cells at a 1:1 ratio, both 
MCF7 ESR1 mutant cell lines were found to be the dominant population in the 
tumor xenografts that were harvested (Figure 2.6A). Interestingly, when MCF7 
ESR1 mutant cell lines are co-inoculated with MCF7 cells in mice supplemented 
with estradiol, both cell lines are represented in the xenograft but MCF7 cells 





ESR1 Y537S and D538G mutations confer resistance to endocrine therapies and 
CDK4/6 inhibitors in vitro 
Since mutations at the 537 and 538 residue of ER can induce ER 
transcriptional activation and estradiol independent growth, it was postulated that 
SERMs and SERDs such as tamoxifen and fulvestrant respectively, might still be 
effective at inhibiting mutant ERα. Previous overexpression studies noted that 
while ESR1 Y537S and D538G mutations do confer resistance to antiestrogens, 
higher doses of antiestrogens are needed to bring ER transcriptional activity 
levels close to that of wild type ERα via a luciferase reporter assay7-10. Therefore, 
we wanted to investigate whether tamoxifen and fulvestrant can inhibit MCF7 
ESR1 mutant cell line proliferation.  
MCF7 wild type and MCF7 ESR1 mutant cell lines exhibit a dose 
dependent response to increasing doses of fulvestrant but both MCF7 ESR1 
mutant cells are notably more viable in the presence of 1nM fulvestrant 
compared to MCF7 wild type cells (Figure 2.7A). Similarly, MCF7 wild type and 
MCF7 ESR1 mutant cells demonstrate a dose dependent response to tamoxifen 
with MCF7 ESR1 mutants demonstrating increased viability when treated with 
10nM tamoxifen compared to MCF7 wild type cells (Figure 2.7B). Consistent with 
previous reports, while the ESR1 Y537S and D538G mutation confers partial 
resistance to tamoxifen and fulvestrant, higher doses are able to reduce viability 
to levels similar to MCF7 wild type cells.  
Palbociclib, a selective inhibitor for cyclin dependent kinase (CDK) 4 and 
6, has been shown to effectively inhibit luminal ER-positive cell lines but not 
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nonluminal/basal subtypes in the preclinical setting57. Recently, the PALOMA-3 
clinical trial involving hormone receptor positive/HER2 negative metastatic breast 
cancer patients who have progressed on endocrine therapies demonstrated that 
the combination of palbociclib with fulvestrant improved progression free survival 
compared to fulvestrant plus placebo62. We wanted to investigate whether ESR1 
activating mutations influence sensitivity to palbociclib. Interestingly, both MCF7 
ESR1 Y537S and D538G mutant cells were more viable at 10nM and 100nM of 
palbociclib when compared to MCF7 wild type cells (Figure 2.8). MCF7 ESR1 
mutant cell lines only returned to MCF7 wild type levels when treated with 1uM of 
palbociclib. Notably, the addition of 1nM fulvestrant to palbociclib was able to 
completely inhibit both MCF7 ESR1 Y537S and D538G mutant cells to MCF7 
wild type levels (Figure 2.9A). However, the combination of palbociclib with 
tamoxifen was not effective in inhibiting the MCF7 ESR1 mutants (Figure 2.9B). 
To ensure that ESR1 mutations did not confer a broad resistance to 
chemotherapies, MCF7 ESR1 Y537S and D538G were exposed to low doses of 
paclitaxel.  At 10nM of paclitaxel, MCF7 ESR1 Y537S and D538G mutant cells 
exhibited similar sensitivities compared to MCF7 wild type cells (Figure 2.10).  
 
ESR1 Y537S mutant cells are more resistant to endocrine therapies than ESR1 
D538G in co-cultures 
 In order to further model how ESR1 mutations can arise from under 
selection by endocrine therapies, we cultured MCF7 parental cells in vitro with 
both MCF7 ESR1 mutant cell lines at a 1:1 ratio in serum supplemented media 
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containing 1nM E2 with either 10nM tamoxifen or 1nM fulvestrant. Concordant 
with Figure 2.7A and 2.7B, both MCF7 ESR1 Y537S and D538G cell lines were 
selected under anti-estrogen therapies after three to four weeks (Figure 2.11A 
and 2.11B). Interestingly, after 3 weeks MCF7 ESR1 Y537S mutant cells were 
found to be selected at a quicker rate compared to MCF7 ESR1 D538G mutant 
cells. MCF7 parental and MCF7 ESR1 D538G mutant co-cultures were grown for 
an additional week but the ratios of wild type to D538G mutants remained 
unchanged (Figure 2.11B). Additionally, the fraction of MCF7 ESR1 Y537S 
mutant cells were found at a higher percentage in co-inoculations compared to 
MCF7 ESR1 D538G mutant cells (Figure 2.6B). These results suggest that the 
ESR1 Y537S mutation may confer a more oncogenic phenotype compared to the 
ESR1 D538G mutation. 
 
ESR1 Y537S outcompete ESR1 D538G in vitro and in vivo 
 To determine whether the ESR1 Y537S mutation is more activating 
compared to the ESR1 D538G mutation, MCF7 ESR1 Y537S and MCF7 ESR1 
D538G cell lines were cultured together in serum supplemented media with and 
without estradiol. When co-cultured in serum supplemented media, MCF7 ESR1 
Y537S cells are able to outcompete MCF7 ESR1 D538G cells (Figure 2.12A). 
However, when these co-cultures are grown in serum supplemented media with 
estradiol, both cell lines are found at equal ratio, suggesting potential differences 
in ligand independent signaling between the ESR1 Y537S and ESR1 D538G 
mutants when cultured together.  
23 
 
In order to address any difference in proliferation rates not seen in cell 
proliferation assays (Figure 2.3A and 2.3B), MCF7 ESR1 Y537S and MCF7 
ESR1 D538G cell lines were cultured separately in serum supplemented media 
with and without estradiol. When both MCF7 ESR1 mutant cell lines were 
harvested independently and combined at 1:1 volumes, both cell lines were 
found at equal ratios, implying that the increased competition of the ESR1 Y537S 
mutation compared to the ESR1 D538G mutation is not due to differences in 
proliferation rates (Figure 2.12B). Further, in order to see if this difference could 
be seen in vivo, MCF7 ESR1 Y537S mutant cells were co-inoculated with the 
MCF7 ESR1 D538G cells in mice with and without estradiol supplementation. 
Under both conditions, MCF7 ESR1 Y537S were found at a higher percentage 
compared to the MCF7 ESR1 D538G cells (Figure 2.13A and 2.13B). Notably, 
cells that were inoculated subcutaneously in mouse 14 did not form a large tumor 
(data not shown) and the ratios between the MCF7 ESR1 Y537S and ESR1 
D538G mutants were nearly equivalent, hinting that the competition between the 
ESR1 Y537S and D538G mutant is, at least in part, mediated by the interaction 
between both mutant cell lines. 
 
Increased competition of ESR1 Y537S mutant compared to ESR1 D538G mutant 
is not through paracrine signaling 
Since MCF7 ESR1 Y537S cells were able to outcompete the MCF7 ESR1 
D538G cells when cultured in serum supplemented media in vitro, we wanted to 
investigate whether this phenotype was mediated through paracrine signaling or 
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cell-cell interaction via transwell experiments. By two weeks, MCF7 ESR1 Y537S 
cells outcompeted MCF7 ESR1 D538G cells at a 3:1 ratio (Figure 2.12A). When 
MCF7 ESR1 Y537S and MCF7 ESR1 D538G were cultured in transwells with 
MCF7 ESR1 Y537S on plates, both the MCF7 ESR1 Y537S and MCF7 ESR1 
D538G cells were found to be lower but the MCF7 ESR1 D538G cells were not 
found at the expected 3:1 ratio (Figure 2.14A). Additionally, to control for 
proliferation differences on transwells and plates, MCF7 ESR1 D538G cells were 
grown on plates with both ESR1 mutants grown in transwells. No appreciable 
difference was observed between MCF7 ESR1 Y537S and MCF7 ESR1 D538G 
cells cultured on transwells with MCF7 ESR1 D538G cells grown on plates 
(Figure 2.14B). These results suggest that a diffusible paracrine factor is likely 
not mediating the increased competition of MCF7 ESR1 Y537S cells when 
cultured together with MCF7 ESR1 D538G cells.  
 
ESR1 Y537S cells outcompete ESR1 D538G cells through growth suppression  
 Since MCF7 ESR1 Y537S cells were found in a higher fraction when 
cultured together with MCF7 ESR1 D538G cells, we wanted to assess whether 
this was a growth stimulatory effect on the MCF7 ESR1 Y537S cells, a growth 
suppressive effect on the MCF7 ESR1 D538G cells or a combination of both. In 
order to address this, MCF7 ESR1 Y537S and D538G cells were plated singly or 
cultured together in serum supplemented media and grown for two weeks without 
passaging. After two weeks, the total amount of MCF7 ESR1 Y537S and MCF7 
ESR1 D538G cells found in the co-cultures were found to be lower compared to 
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their respective single cultures (Figure 2.15). However, MCF7 ESR1 D538G cells 
were found dramatically lower than the MCF7 ESR1 Y537S cells, suggesting that 
both ESR1 cell lines suppress the other mutant cell line but the MCF7 ESR1 
D538G cells were more suppressed.  
 
Discussion 
While targeted drugs such as tamoxifen and fulvestrant that antagonize 
ER have been highly effective therapies in the treatment of luminal breast 
cancer, acquired resistance after prolonged exposure remains a major hurdle to 
curative treatment. It has been understood that reduced expression of ER, the 
upregulation of HER2 and activation of other escape signaling pathways have 
been shown to be associated with insensitivity to anti-estrogen therapies40-43. 
Recently, the discovery of activating mutations in the LBD of ESR1 has garnered 
interest due to their potential role in endocrine resistance. These studies have 
highlighted that mutations at the 537 and 538 residue of ER are able to induce 
ligand independent transcription and partial resistance to anti-estrogen 
therapies6-10. Indeed, understanding how these ESR1 mutations are selected, 
promote transformation, and confer resistance to endocrine therapies permit 
opportunities for the development of novel therapies and drug combinations to 
overcome endocrine resistance. 
Notably, ESR1 mutations can induce endocrine resistance when mutant 
ESR1 cDNA is overexpressed and driven by a non-endogenous promoter. While 
these overexpression approaches underscore the importance of ESR1 mutations 
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as a resistance mechanism, they potentially overestimate the degree of 
endocrine resistance that would be found in breast tumors that are hormone 
refractory63. Importantly, studies investigating resistance to lapatinib have 
demonstrated that the HER2 L755S mutation imparts resistance when 
overexpressed but not when it is endogenously expressed as a single copy51-52. 
Moreover, overexpression of mutant KRAS, but not single knock in, is able to 
induce cellular transformation and tumor formation50, 55. In light of this, we sought 
to develop a more clinically relevant model where ESR1 mutations are not 
overexpressed. Here, we utilized AAV-mediated gene targeting to knock in the 
ESR1 Y537S and D538G mutation into an ER-expressing breast cell line model 
to analyze the effect on transformation and endocrine resistance when driven by 
an endogenous promoter. Both ESR1 Y537S and D538G mutants demonstrate 
ligand independent proliferation and tumor xenograft formation without estrogen 
supplementation. Interestingly, tumor xenografts formed by the MCF7 ESR1 
Y537S and D538G mutants in the presence of estrogen supplementation were 
significantly larger, suggesting that the both ESR1 mutants are still estrogen 
responsive in vivo and can likely be inhibited by anti-estrogen therapies.  
Consistent with previous reports, the ESR1 Y537S and D538G mutations confer 
partial resistance to tamoxifen and fulvestrant but are inhibited at higher doses6-8, 
10. However, it is unclear whether the dose of tamoxifen and fulvestrant given to 
patients is high enough to inhibit the proliferation of these mutant cells. Indeed, 
our study demonstrates ESR1 Y537S and D538G mutants can be selected for 
when treated with non-lethal doses of fulvestrant or tamoxifen and may require 
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more potent ER antagonists or other combinations therapies to circumvent drug 
resistance.  
Clinical trials have highlighted the effectiveness of combining the CDK4/6 
inhibitor, palbociclib, with either letrozole or fulvestrant in the treatment of ER-
positive breast cancers62, 64. Palbociclib has been shown to be effective in 
targeting luminal breast cancer cell lines in vitro57 and to the best of our 
knowledge, our study is the first to highlight that the ESR1 Y537S and D538G 
mutations also confer resistance to palbociclib. While a patient derived xenograft 
(PDX) tumor model containing the ESR1 D538G mutation was found to be 
resistant to palbociclib, immunohistochemistry analysis revealed a loss of Rb 
expression which has been attributed for the lack of response65.  In our study, 
ESR1 LBD mutants demonstrate resistance when treated with either fulvestrant 
or palbociclib alone but are sensitive to the combination of these two drugs. 
Notably, the addition of fulvestrant to palbociclib more potently inhibits ESR1 
mutants compared to tamoxifen and palbociclib. We hypothesize that the 
combination of fulvestrant with palbociclib target different molecular pathways 
compared to the combination of tamoxifen and palbociclib, but further work is 
needed to test this hypothesis. Ongoing clinical work will reveal whether this 
combination is effective in treating patients harboring ESR1 mutations.  
It is now well appreciated that different somatic alterations within the same 
gene can induce significant differences in transformation and response to 
targeted therapies66-67. Interestingly, despite both ESR1 Y537S and D538G 
mutations being found in the ligand binding domain, our study illustrates that the 
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ESR1 Y537S mutant is more activating in vitro and in vivo when coupled with 
ESR1 D538G mutant. Recent reports investigating the biophysical and structural 
biology of the ESR1 Y537S and D538G mutations have identified differences in 
binding affinity to co-activators68. In the absence of ligand, the ESR1 Y537S 
protein binds the steroid receptor coactivator 3 nuclear receptor domain (SRC3 
NRD) with significantly increased affinity compared to the ESR1 D538G protein. 
It is possible that this differential binding affinity to co-activators in the absence of 
estrogen is responsible for the increased competition we observed when ESR1 
Y537S cells are cultured with ESR1 D538G mutant cells. Further work is required 
to clarify whether these differential binding affinities can be exploited 
therapeutically but suggest our isogenic cell lines can be utilized to development 
and testing of mutation specific targeted therapies.  
There are limitations to this study, notably the usage of only one ER-
positive breast cancer cell line to generate our ESR1 mutant panel. Moreover, 
MCF7 cells contain two copies of the activating PIK3CA E545K mutation and one 
wild type copy of PIK3CA and knock in of the PIK3CA E545K in a cell line model 
has been shown to induce PI-3 kinase and MAP kinase signaling69-70. As such, it 
is important to examine the effects of these ESR1 mutations on transformation 
and endocrine resistance in the context of the MCF7 genome. Mutant PIK3CA 
has been shown to cooperate with oncogenic changes in TP53 and HER2 and it 
is feasible to imagine cooperativity between mutant PIK3CA and ESR1 on 
transformation and drug resistance52, 71. However, previous studies have cited 
patients harboring both a PIK3CA and ESR1 mutation, providing evidence that 
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this isogenic model is still clinically relevant 6, 8. In conclusion, our study utilizing 
an isogenic model cell line model to study ESR1 mutations suggest that a single 
mutant copy of ESR1 is sufficient to induce estrogen independent proliferation 
and tumor formation. While ESR1 mutations confer resistance to anti-estrogen 
therapies and CDK4/6 inhibitors, they are sensitive to combination therapies, 
specifically the combination of fulvestrant and palbociclib. Additionally, our study 
demonstrates that although both ESR1 mutations are found in the same domain 
and induces resistance to endocrine therapies, they confer differential degrees of 
transformation. This has important clinical considerations for the development of 
targeted mono- and combination therapies for the treatment and prevention of 
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Introduction 
Our ability to adequately treat and manage disease hinges on an accurate 
and proper diagnosis. Historically, tissue biopsies have been the gold standard in 
oncology, providing histopathological information on whether or not a lesion is 
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malignant. In addition to determining whether a lesion may be malignant, tissue 
biopsies provide a reservoir for genetic information. In a seminal study, Wood et 
al. utilized Sanger sequencing to unravel the range and frequencies of genetic 
alterations that make up breast and colorectal tumors, now known as the “cancer 
genome landscape”46. The hope is that this genetic information can reveal what 
genes might be altered or disrupted that promote cancer, namely “drivers,” and 
how these alterations can be targeted.  
However, despite their utility, there are challenges to acquiring tissue 
biopsies and how they are processed for subsequent analysis. Obtaining 
biopsies is inherently invasive and depending on the stage of the disease and the 
amount of tissue isolated, can be limiting in quantity for genomic analysis. Most 
tumor tissues are subsequently preserved in formalin-fixed, paraffin-embedded 
(FFPE) blocks for pathological interpretation and staining. However, this process 
crosslinks and fragments DNA, jeopardizing their structural integrity and 
introduces challenges for sequencing and interrogating genomic alterations. 
Lastly, cancer is an inherently heterogeneous disease, where different areas of 
the same tumor or different metastases can arise from different subclonal 
populations, namely intra- and intertumoral heterogeneity, respectively. 
Biopsying a single site provides only a single spatial and temporal snapshot and 
unlikely to reflect the dynamic tumor heterogeneity in patients72.  
In light of this, development of noninvasive techniques such as liquid 
biopsies as a surrogate for tissue biopsies has garnered increased interest. 
Compared to tumor biopsies, blood draws are minimally invasive and provide a 
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source of cell free DNA (cfDNA) for serial sampling to monitoring disease. Cell 
free DNA is derived from all cells, including both normal and cancers cells, with 
the latter more commonly referred to as circulating tumor DNA. Since the DNA of 
cancer cells harbors somatic alterations, that is, mutations, amplifications and 
rearrangements not present in normal cells, cancer DNA presents a unique 
“fingerprint” that can be used to differentiate cancer from non-cancerous cells. 
Indeed, studies have demonstrated that the mutational profile generated from 
analyzing ctDNA generally reflects the same somatic alterations found in 
patients’ cancers, and can sometimes capture mutations not present in the initial 
biopsy73-74.  
The identification of ESR1 mutations that are responsible for endocrine 
therapy resistance in ER-positive breast cancers opens the door for developing 
new diagnostic tools and novel targeted therapies6-8, 10, 75. However, given the 
problem of tumor heterogeneity, the true frequency of ESR1 mutations may be 
underestimated, since mutational profiles can vary between different sites of 
metastatic disease72.  Most studies heretofore have employed NGS of a single 
metastatic site, and indeed, one study demonstrated an ESR1 mutation in a liver 
metastatic biopsy but not a lung metastasis obtained from the same patient10.  
Further, in many cases, fresh biopsies of metastatic disease cannot be safely 
obtained and/or archival tissues are inadequate or unavailable. Finally, these 
mutations appear to evolve during endocrine treatment, and therefore a non-
invasive method of monitoring patients might provide an opportunity to alter 
therapy as these mutations emerge.  Thus, there is need to develop non-invasive 
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methods to quickly assess mutational profiles across multiple metastases from 
an individual patient. 
 Recently, we and others have examined the use of circulating cell-free 
plasma tumor DNA (ptDNA) as a biomarker for cancer detection76-83.  It is known 
that DNA molecules from both normal and cancer cells are shed or released into 
the circulation84-85. Because DNA from cancer cells harbor somatic mutations and 
rearrangements, these can serve as specific genetic biomarkers for the presence 
of cancer.  Further, the quantity of ptDNA directly correlates with tumor burden 
and response to therapies86.  Additionally, several groups have demonstrated the 
ability to detect the presence of acquired drug resistance mutations in ptDNA87-88, 
which opens the possibility for earlier therapeutic intervention.  More recently, our 
group has shown that a next generation digital PCR platform, termed droplet 
digital PCR (ddPCR) has exquisite sensitivity and specificity for detecting cancer 
mutations in early stage breast cancer patients82. We hypothesized that ddPCR 
could be a more sensitive platform for ESR1 mutation detection in metastatic 
breast cancer patients and may show a more accurate frequency of these 
mutations in ER-positive disease.  To test this hypothesis, we performed ddPCR 
for ESR1 mutations on cell-free plasma samples from patients with metastatic 
breast cancer and compared ESR1 mutations in ptDNA with NGS of metastatic 







We enrolled a total of 23 patients in two separate cohorts (Figure 3.1) from 
UMCCC and JHSKCCC.  Systemic endocrine therapies are shown (Table 3.1), 
though many patients also received prior chemotherapies. To determine if we 
could identify circulating ESR1 mutations in patients with known tissue ESR1 
status, we initially performed a retrospective analysis by obtaining plasma 
samples from eleven patients who had previously undergone NGS of a 
metastatic lesion (Table 3.2). Plasma DNA was obtained from these patients less 
than 1 year after their tissue biopsy (median = 145 days, range 54 to 344 days).  
Eight of these patients (patients 1-8) had ESR1 mutations identified via NGS in 
their metastatic biopsies, and three patients (patients 9-11) had wild type ESR1.  
Patients 1- 3 had previously been reported as having an ESR1 tissue mutation8 
identified via the MiONCOSEQ program at UMCCC89, while patients 4-8 had 
ESR1 mutations identified at JHSKCCC using a commercial platform 
(Foundation Medicine).  All patients had documented ER-positive disease, and 
NGS was performed on samples representing diverse metastatic sites (Table 
3.1).  The plasma specimens were interrogated for all three ESR1 hotspot 
mutations: Y537S, Y537N and D538G, using mutation specific probes and 
ddPCR as previously reported82. These three mutations were chosen as they 
collectively represent the most frequent ESR1 mutations in metastatic disease75.  
As demonstrated in Figure 3.2, each probe was specific for its respective 
mutation using Y537S, Y537N and D538G mutant and wild type templates.  As 
shown in Table 3.2, ddPCR successfully detected all mutations in ptDNA that 
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were detected in the metastatic biopsy, confirming the ability to detect mutations 
present within the tumor sample. The majority of patients had significant tumor 
burden with multiple metastatic sites of disease (Table 3.4), though patient 5 had 
no evidence of disease after removal of her metastatic lesion.  Indeed, although 
she did have a circulating ESR1 mutation (D538G), it was detected at a relatively 
low fractional abundance (0.03%) in her plasma.  
In addition to harboring the known tissue mutation (Y537S in her 
circulation), patient 1 also had a low fractional abundance (0.01%) of a second 
circulating mutation, D538G, which was not detected in the metastatic tissue.  It 
should be noted, however, that her blood was drawn 186 days after biopsy, and 
thus a new subclonal population within the same metastatic site could have been 
present at the time of blood draw.  Similarly, patient 9 was wild type for ESR1 in 
the metastatic lesion but showed a D538G mutation at a relatively low fractional 
abundance in a plasma sample obtained 54 days after biopsy. These results 
suggest that ddPCR of ptDNA can reliably detect ESR1 mutations first identified 
in metastatic tissues and may also detect subclonal populations in the metastatic 
biopsy below the limit of detection by NGS, or mutations from other sites of 
disease. 
 The presence of two additional mutations in patients 1 and 9 may have 
been due to clonal evolution in the interim between tissue biopsy and blood draw 
for ptDNA analysis. To address this possibility, we prospectively enrolled eight 
additional ER-positive patients (patients 12-19) to simultaneously collect 
metastatic tissue biopsies and blood for NGS and ddPCR analysis, respectively.  
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As controls, we also obtained metastatic tissue and blood samples from four ER-
negative patients (patients 20-23).  All patients were enrolled at UMCCC except 
patient 19 who was enrolled at JHSKCCC.  As shown in Table 3.3, sufficient 
tissue could not be obtained for patients 12 and 19, while patient 14 did not have 
adequate sample for NGS analysis.  These patients highlight the fact that 
metastatic biopsies are not always obtainable and that the amount of tissue can 
preclude genomic analysis. 
 After plasma DNA extraction, ddPCR analysis was performed in a blinded 
fashion.  As seen in Table 3.3, all patients had blood drawn at the time of tissue 
biopsy, except two patients (patients 20 and 21) had blood drawn 5 and 3 days 
after biopsy, respectively, for logistical reasons.  Of the five ER positive patients 
for whom tissue NGS results could be obtained, no ESR1 mutations were 
identified in their metastatic biopsies.  However, ESR1 mutations were detected 
in the ptDNA samples from three of these patients (patients 13, 16, and 18), all of 
whom had their blood drawn the same day as biopsy.  Of note, patient 16 was a 
known germline BRCA2 mutation carrier and may have had a primary peritoneal 
(ovarian) carcinoma concurrent with her liver metastases, thus obfuscating the 
origin of the liver lesion.  As expected, the ER-negative patients (patients 20-23) 
did not have detectable ESR1 mutations in their ptDNA.  The difference in 
mutational status was statistically significant between tissue and blood using two-
tailed Fisher’s exact test (p<0.0186).  
Interestingly, patient 14, who was ER-positive, had a high fractional 
abundance of two distinct circulating ESR1 mutations (Y537S, 5.02%; D538G, 
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2.62%).  Her only metastatic site amenable to biopsy was a pleural effusion, 
which was inadequate for NGS. The ptDNA from this patient collected 
concurrently at the time of biopsy contained two distinct mutations at differing 
allelic frequencies, suggestive of two separate clonal populations. This was 
similar to patient 1, and suggestive that the mutations were on separate alleles.  
To prove this, we developed a dual mutation specific probe and positive control 
template.  As shown in Figure 3.3, this probe has specificity for a synthetic allele 
harboring both mutations.  Analysis of ptDNA from patients 1 and 14 using this 
probe showed no positive signals, demonstrating that the two ESR1 mutations 
are on separate alleles, further supporting that these ESR1 mutations are derived 
from different clonal populations.  
 An additional noteworthy case is patient 19, who presented at the time of 
diagnosis with wide spread, bone only ER-positive metastatic disease.  She 
initiated treatment with the AI letrozole, and after 1 year of therapy restaging 
scans showed disease stabilization of her bony metastasis, and complete 
resolution of her breast tumor.  She elected to have bilateral mastectomies, 
which revealed that the affected breast and the contralateral breast had no 
evidence of disease.  She remained on letrozole for 5 years with stable disease. 
She enrolled in our study while still in remission, although restaging scans 
continued to demonstrate only prior bony lesions, which were not amenable to 
biopsy. Nonetheless, her plasma demonstrated the presence of the Y537N 
mutation. Because of her unusual presentation, this is the only patient in our 
cohort that had developed an ESR1 mutation after exposure to a single 
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endocrine therapy, letrozole.  Subsequently, she had an asymptomatic elevation 
in her tumor markers and her therapy was changed to fulvestrant. Clinically she 
remains without evidence of progression and has had stabilization of tumor 
markers.  Although other studies have suggested that AIs may be the class of 
endocrine therapies that selects for LBD ESR1 mutations90, most studies have 
enrolled patients who have received multiple lines of endocrine therapy in both 
the adjuvant and metastatic settings, which precludes any definitive conclusions. 
This patient demonstrates that an ESR1 mutation can indeed occur after 
prolonged exposure to an AI without other endocrine or systemic therapies, and 




 There are several important conclusions with potential therapeutic 
implications derived from our study.  First, we have demonstrated that ESR1 
mutations can be readily detected using ddPCR on plasma from patients with 
metastatic ER-positive disease after progression on endocrine therapies. Given 
challenges that can arise in obtaining a metastatic biopsy as encountered in this 
study, the use of ptDNA as a “liquid biopsy” holds great promise for future 
molecular analysis of human cancers.  Moreover, monitoring for emergence of 
mutated clones by repeat sampling can be more easily performed with a simple 
blood test than with multiple tissue biopsies.  Second, we demonstrate that blood 
can be a more sensitive source for detecting ESR1 mutations.  In our study two 
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patients harbored a distinct, second ESR1 mutation not present in the 
corresponding metastatic biopsies. Perhaps more importantly, one patient in 
cohort 1 and three patients in cohort 2 had wild type ESR1 in their metastatic 
biopsies, but had ESR1 mutations detected in their corresponding ptDNA 
sample. These results support the increasingly recognized problem of tumor 
heterogeneity and are in agreement with a prior report demonstrating differences 
in ESR1 mutation status between two metastatic sites within the same patient10. 
Third, our results support the previously proposed hypothesis that ESR1 LBD 
mutations may be selected for after progression on AIs8. This was particularly 
striking in patient 19, who was positive for an ESR1 mutation and had received 
only prolonged exposure to letrozole. Fourth, our study shows that ddPCR of 
ptDNA is capable of detecting ESR1 mutations even in patients who have no 
radiographic evidence of disease. Although the clinical validity and utility of this 
observation remains to be proven, we suggest that detecting drug resistant 
mutations may afford the opportunity to change therapies earlier or enroll in trials 
of novel targeted therapies, which may lead to improved outcomes for patients.  
Finally, the frequency of circulating ESR1 mutations in our study is notably higher 
than prior reports using a single metastatic biopsy.  The majority of studies thus 
far have detected ESR1 mutations only in patients with metastatic disease after 
progression on endocrine therapies, though one study did find a low incidence 
(3%) in primary tumors7.  The largest study to date of ESR1 mutations in 
metastatic tissue biopsies suggests an overall frequency of 12%, with a 
frequency of 20% in a subgroup analysis of patients who received an average of 
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7 lines of therapy75.  However, we found additional mutations not detected by 
sequencing of metastatic lesions.  In cohort 1, two additional mutations were 
discovered: patient 1 who had an additional ESR1 mutation found in ptDNA 
compared to her metastatic biopsy, and patient 9 who was wild type for ESR1 on 
her metastatic tissue sample.  Additionally, in cohort 2, we detected seven ESR1 
mutations in six of the eight ER-positive patients not detected in metastatic 
biopsies, although three of these patients did not have adequate tissue for NGS. 
These results highlight the potential impact of using blood as a more sensitive 
and accessible source for mutation detection.   
 The higher frequency of ESR1 mutations in blood compared to biopsied 
tissues could be due to several non-overlapping reasons. As mentioned, tumor 
heterogeneity can lead to the detection of mutations in ptDNA that are present in 
other non-biopsied metastatic sites. It is also conceivable that sampling error of 
biopsies may miss subclonal populations in a given metastatic lesion, and/or 
certain clonal populations may have a propensity for releasing ptDNA versus 
other clonal variants.  For example, it is possible that ptDNA shed from CTCs is 
more abundant than ptDNA derived from other metastatic sites.  Further studies 
are needed to clarify the origins and kinetics of ptDNA as related to sites of 
metastases, and any underlying biology that may favor the enrichment of clonal 
populations that shed higher versus lower amounts of ptDNA into the circulation. 
There are limitations of our study, most notably the small sample size, 
which prevents our assessing the true prevalence of ESR1 mutations in plasma 
from patients with ER-positive breast cancer.  Further, we only queried for the 
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three most common ESR1 LBD mutations, and it is likely ptDNA contains other 
ESR1 mutations associated with endocrine therapy resistance.  Although 
additional ESR1 LBD mutations have been described at lower frequency6-8, 10, 75, 
we did not identify these mutations by NGS of tissues in the retrospective cohort, 
and they were therefore not queried by ddPCR. In addition, because these 
mutations are all in close proximity to one another, each ESR1 ddPCR mutation 
probe was run separately due to potential competition for the same template 
molecule, which could theoretically decrease the sensitivity for any given probe.  
This can limit the number of mutations that can be assayed due to low amounts 
of plasma DNA.  However, this limitation may have led us to underestimate the 
prevalence of ESR1 mutations in our study. 
In summary, we confirm the feasibility of detecting ESR1 mutations in 
ptDNA, and that plasma may prove to be a superior source than metastatic 
biopsies for ESR1 mutation detection.  However, the clinical utility of using 
ddPCR for ESR1 mutations to guide therapy for patients requires careful 
prospective study before adoption into clinical practice.  It is unknown what allelic 
frequency of ESR1 mutation is associated with symptomatic disease 
progression, and whether changing endocrine therapies can improve patient 
outcomes.  Nevertheless, the ability to detect ESR1 mutations in the plasma of 
patients, independent of the tissue mutational status, provides the foundation for 








































































Isogenic modeling of ESR1 activating mutations 
Cell Culture 
The MCF7 cell line91 and its derivatives were maintained in DMEM media 
with 5% fetal bovine serum (Life Technologies, Carslbad, CA) and 1% Penicillin-
Streptomycin (Life Technologies). For assays involving MCF7 and its derivatives, 
DMEM:F12 (1:1) media without phenol red was supplemented with 0.5% (serum 
starved) or 10% (serum supplemented) charcoal dextran stripped fetal bovine 
serum unless otherwise noted. MCF7 parental and HEK-293T cell lines were 
purchased from ATCC (Manassas, VA). Parental cell lines were authenticated 
via short tandem repeat profiling analysis at the Johns Hopkins Genetic 




Gene Targeting and Generation of ESR1 Mutation Cell lines 
Gene targeting of ESR1 in MCF7 cells was carried out using recombinant 
AAV vectors as previously described70.  Briefly, gene targeting of ESR1 was 
carried out using one AAV vector for both the ESR1 Y537S and D538G 
mutations. AAV vectors were produced by ligating wild type homology arms 
generated by PCR into an AAV plasmid backbone (Agilent, La Jolla, CA). Site 
directed mutagenesis by overlap extension PCR was utilized to generate the 
ESR1 Y537S and D538G mutations within the targeting construct.  Infectious 
virus was prepared by co-transfecting HEK-293T cells with pHelper, pRC 
(Agilent) and the respective ESR1 mutation carrying rAAV targeting plasmid. 
Approximately 106 cells were used for each viral infection. Targeted neomycin 
resistant clones were isolated via a modified PCR screening strategy50 and the 
cells were then exposed to Cre-expressing recombinant adenovirus to remove 
the neomycin cassette. All isolated clones were confirmed by Sanger sequencing 
and droplet digital PCR of genomic DNA and cDNA to ensure the clones 
harbored the intended ESR1 mutation as single copies and had equal allelic 
expression. Single-stranded cDNA was generated using First Strand cDNA 
Synthesis Kit (Amersham Biosciences). Two clones were isolated for each ESR1 
mutation as well as a targeted wild type control for the ESR1 exon 10 locus. 
Primer sequences for PCR amplification, mutagenesis, targeting and sequencing 





Cell proliferation assays  
Exponentially growing cells were washed twice with clear HBSS and 
seeded at a density of 1x104 cells/well in 12 well plates in serum starved media 
for 24hrs. On day 0, medium was changed to serum supplemented media with 
and without 1nM β-estradiol (Sigma-Aldrich, St Louis, MO). Medium was 
changed on day three. Cells were harvested on the indicated dates and counted 
using a Beckman Coulter counter and the relative proliferation was calculated 
using the average proliferation for each cell line and the first time point as a 
reference. Results from the ESR1 mutant cell lines represent data from two 
clones unless otherwise noted. All cell lines were counted in triplicate.  
 
Xenograft assays 
For each group, five randomly distributed 8- to 10-week-old female 
athymic nude mice (Harlan Laboratories, Indianapolis, IN), with and without 
estrogen pellet supplementation, were injected subcutaneously in either flank 
with 2x106 cells in a 200uL mixture of 80% growth factor reduced Matrigel (BD 
Biosciences, San Jose, CA) and 20% 1X clear HBSS. For co-inoculations, 1x106 
MCF7 cells were combined with either of the 1x106 MCF7 ESR1 mutant cells 
before injections. For co-inoculations involving the MCF7 ESR1 mutants, 1x10
6
 
of the MCF7 ESR1 Y537S mutant cells was combined with 1x106 of the MCF7 
ESR1 D538G mutant cells before injections. Tumor volumes were analyzed at 
the indicated dates and calculating by multiplying the length, width and height for 
each tumor volume. 
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All animal experiments were performed in accordance with institutional 
and The National Institute of Health Guide for the Care and Use of Laboratory 
Animal guidelines. 
 
Drug inhibitor assays 
Fulvestrant and paclitaxel were obtained from Sigma-Aldrich and were 
dissolved in dimethyl sulfoxide (DMSO). 4-hydroxytamoxifen was also obtained 
from Sigma-Aldrich and dissolved in ethanol. Palbociclib was obtained from 
Selleck (Houston) and dissolved in DMSO. 3x103 cells/well were seeded into 12 
well plates and serum starved media for 24hrs. On day 0, media was changed to 
serum supplemented media with 1nM β-estradiol and the indicated concentration 
of drug or appropriate vehicle control. Cells were harvested on day 7 and 
counted using a Beckman Coulter counter. Percent viability was calculated using 
the average number of cells for each cell line at the indicated concentration 
normalized to the appropriate vehicle control. Results from the ESR1 mutant cell 
lines represent data from two clones unless otherwise noted. All cell lines were 
counted in triplicate. 
 
Co-culture and co-inoculation assays 
For co-culture assays, 1-2x105 exponentially growing MCF7 cells were 
seeded with 1-2x105 exponentially growing MCF7 ESR1 mutant cells into T25 
flask in serum supplemented media with and without 1nM β-estradiol. The same 
amount of cells was also used for MCF7 ESR1 Y537S and MCF7 ESR1 D538G 
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co-culture experiments. Cells were passaged once a week with 1-2x105 cells 
harvested for genomic DNA extraction at the time points indicated. Genomic 
DNA was digested and purified for ddPCR analysis. 
For co-inoculation studies, animals were euthanized when tumor volumes 
reached 200-300 cm3 and xenografts were excised and flash frozen. Tumor 
xenografts were homogenized with Biomasher tissue grinder (Kimble, Nashville, 
TN) and resuspended in PBS. Genomic DNA was extracted using QIAamp DNA 
Blood Mini Kit (Qiagen) and subsequently digested and purified for ddPCR 
analysis.  
 
Droplet digital PCR 
For all droplet digital PCR assays, genomic DNA was digested with CviQ1 
restriction enzyme and PCR purified using QIAquick PCR Purification kit 
(Qiagen) before samples were subjected to ddPCR analysis unless otherwise 
noted. The QX200 platform (Bio-Rad) was then used for ddPCR per the 
manufacturer’s protocols with the ddPCR primers and probes listed in Table 2.9-
2.10. The mutant frequency was determined by the number of mutant DNA 
alleles to the total (mutant plus wild-type) DNA alleles and the wild type 
frequency was determined by the number of wild type DNA alleles to total for 
each sample assayed. 
For the co-culture and co-inoculation assays with MCF7 parentals, the 
mutant and wild type frequency were used to calculate the percentage of MCF7 
ESR1 Y537S and D538G mutant cell lines to MCF7 parental present in each 
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mixture. For co-inoculations involving the MCF7 ESR1 mutants, the mutant 
frequency of ESR1 Y537S and ESR1 D583G were used to calculate the 
percentage of ESR1 mutants present in each mixture.  
 
Transwells 
Exponentially growing cells were washed twice with clear HBSS and 
seeded at 2x103 cells in 6 well plates or transwell inserts (VWR) in serum 
supplemented media on day 0. On day 1, cells on the transwells inserts were 
transferred to the 6 well plates and grown for 13 days. Cells were not passaged 
and medium was added after one week. Cells were harvested after 13 days and 




All statistical analyses were performed using GraphPad Prism 5 software 
(GraphPad Software). *Unpaired Student’s T tests, 1-way ANOVA and 2-way 
ANOVA tests were used to compare the experimental groups to the 
corresponding controls. Significance levels are indicated by the use of one or 








Detection of ESR1 mutations in circulating plasma tumor DNA from 
metastatic breast cancer patients 
Patient and sample collection  
We conducted this clinical study at the University of Michigan 
Comprehensive Cancer Center (UMCCC) and the Johns Hopkins Sidney Kimmel 
Comprehensive Cancer Center (JHSKCCC).  Men and women with metastatic 
(stage IV) breast cancer were eligible. All patients signed informed consent. For 
the UMCCC cohort, patients were recruited from breast cancer patients 
undergoing a research tumor biopsy of metastatic disease for whole exome 
sequencing through UMCCC’s MiONCOSEQ program8, 89.  In particular, these 
patients were recruited in a companion trial to MiONCOSEQ, designated MiCTC-
ONCOSEQ approved by the University of Michigan Health System IRB. Under 
this protocol, any metastatic breast cancer patients previously enrolled or 
enrolling in the parent MiONCOSEQ protocol were asked to provide blood 
samples for ptDNA collected in BCT DNA tubes (Streck) and CTC analyses (data 
not reported in this publication). For the JHSKCCC cohort, patients were 
consented and enrolled in an ongoing longitudinal tissue and blood repository 
protocol, allowing for research use of human tissues and bodily fluids from 
patients with breast disease. An IRB subprotocol approved for genomic analyses 
of tumor tissues and blood from breast cancer patients of any stage was used to 
obtain metastatic tumor biopsies and subsequent blood samples from ER-
positive metastatic patients. Metastatic tumor samples obtained as FFPE blocks 
and slides were sent for NGS DNA analysis using a commercial source 
(Foundation Medicine).  In this cohort, blood samples of 30ml were collected in 
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EDTA tubes or BCT DNA tubes after patients with ESR1 mutations were 
identified.  Prospective enrollment is also allowed for this protocol. 
 
Isolation and Quantification of ptDNA for ddPCR  
Blood samples and plasma DNA preparation were performed as 
previously described82.  Briefly, plasma was obtained by a double spin centrifuge 
protocol of whole blood to remove cellular contaminants. Blood was centrifuged 
within 1 hour if collected in EDTA tubes and within 7 days if collected in DNA 
BCT (Streck) tubes.  Purified plasma DNA was isolated using the Qiagen 
Circulating Nucleic Acid kit (Qiagen) per the manufacturer’s protocol. The 
isolated plasma DNA was then subjected to high fidelity PCR amplification for 10 
cycles (Phusion, NEB), using the primers listed in Table 3.6. The PCR amplified 
products were then diluted and combined with mutant and wild type probes for 
ESR1 mutation detection in separate reactions for each mutation specific probe 
(Table 3.6). The Bio-Rad QX200 platform was then used for ddPCR per the 
manufacturer’s protocol, with results reported as a percentage or fractional 
abundance of mutant DNA alleles to total (mutant plus wild type) DNA alleles.  
Samples were run in multiple replicates (at least 8) and results averaged as a 
meta-well using the QuantaSoft program as previously described82.  Positive and 
negative controls were included for each assay to control for proper signal gating 
and exclusion of contamination artifacts. At least 10,000 genome equivalents 
were assayed for each patient sample, and negative samples were scored as 
negative only after assaying 100,000 genome equivalents.   
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Synthetic Template Synthesis 
To construct the Y537S, Y537N, D538G and Y537S + D538G synthetic 
templates for specificity controls, a ~1kb genomic DNA fragment of the ESR1 
LBD was amplified by PCR and ligated into the pSEPT vector92.  PCR site 
directed mutagenesis93 was then carried out for each mutation with primers 
designed for overlapping PCR extension to generate all single mutation synthesis 
templates (pY537S, pY537N, pD538G).  Once generated, the pY537S template 
was utilized to create the pY537S+D538G using dual mutation primers.  All 
templates were confirmed by Sanger sequencing.  Primer sequences for PCR 
are provided in Table 3.6. 
 
Statistical Analysis 
In order to quantify the percent ptDNA containing mutant ESR1 in plasma 
samples, a fractional abundance calculation using the QuantaSoft program (Bio-
Rad Technologies) was employed, using the total number of droplets (with and 
without DNA) to calculate the number of DNA molecules as copies/µl, and then 
dividing the number of mutant DNA molecules by the number of total DNA 
molecules (mutant plus wild type), multiplied by 100 to yield a percentage of 
mutant DNA molecules in a sample taking into account a Poisson distribution of 
occupied to unoccupied droplets.  For cohort 2, Fisher’s exact two-tailed test 
(GraphPad) was used to calculate differences in ESR1 mutation status (mutant 
vs. wild type) between tissue and blood using a 2x2 contingency table with 9 
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